PACTR201211000433272已完成未知
A pilot study to optimise controlled human malaria infections in humans with varying degrees of prior exposure to malaria using P. falciparum sporozoites administered by needle and syringe
niveristy of Oxford0 个研究点目标入组 28 人开始时间: 2012年10月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 40 Year(s)（—）
- 性别
- All
入选标准
- •Healthy adults aged 18 to 40 years.
- •Minimum of 4 completed years (Form 4) of secondary education.
- •Able and willing (in the Investigator¿s opinion) to comply with all study requirements.
- •Informed consent to undergo CHMI.
- •Answer all questions on the informed consent questionnaire correctly.
- •Willingness to take a course of curative anti-malaria medication.
- •Agreement to stay in an in-patient unit during a part of the study (from day of administration of PfSPZ Challenge until completion of curative course of atovaquone/ proguanil hydrochloride given either at malaria diagnosis or day 21 post administration of PfSPZ Challenge).
- •Use of effective method of contraception for duration of study (women only).
排除标准
- •¿PCR positive for P. falciparum parasites at screening.
- •¿Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).
- •¿Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
- •¿Current participation in another clinical trial or recent participation within 12 weeks of enrolment.
- •¿Prior receipt of an investigational malaria vaccine.
- •¿Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
- •¿Use of immunoglobulins or blood products within 3 months prior to enrolment.
- •¿Haemoglobinopathy (sickle-cell trait) deemed to interfere with study endpoints
- •¿A history of allergic disease or reactions likely to be exacerbated by malaria infection.
- •¿Contraindications to atovaquone/proguanil hydrochloride.
- •¿History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- •¿History of serious psychiatric condition that may affect participation in the study.
- •¿Any other serious chronic illness requiring hospital specialist supervision.
- •¿Women only; pregnancy, intention to become pregnant or breast-feeding during study.
- •¿Suspected or known current alcohol abuse.
- •¿Suspected or known injecting drug abuse.
- •¿Seropositive for hepatitis B surface antigen (HBsAg).
- •¿Seropositive for hepatitis C virus (antibodies to HCV) with PCR positive for Hepatitis C.
- •¿Positive family history in 1st and 2nd degree relatives < 50 years old for cardiac disease.
- •¿Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
- •¿Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
- •Exclusion Criterion on Day of Challenge
- •¿Acute disease, defined as moderate or severe illness with or without fever (temperature >37.5oC.
研究者
相似试验
尚未招募
不适用
A pilot human study for evaluating effectiveness and safety of CKDGH_M030 on muscular function:randomized double blind placebo controlled trialDiseases of the musculo-skeletal system and connective tissueKCT0004453BiofoodCRO30
尚未招募
2 期
Evaluation of Siddha formulations Nuflm-1 capsule, Spln-2 softgel and Rudn oil-3 in the treatment of neck pain and backpain with sciatica.CTRI/2024/03/064253il
已完成
1 期
A pilot study to increase the in vivo safety and infectivity of an in vitro expanded Plasmodium falciparum 3D7-MBE008 master cell bank in healthy subjectsInfection - Other infectious diseasesMalariaACTRN12619001079134QIMR Berghofer Medical Research Institute2
已完成
不适用
A study to compare two different pedal wart treatments.pedal wartsSkin - Other skin conditionsInfection - Other infectious diseasesACTRN12613000062729Professor Reza Naraghi30
进行中（未招募）
1 期
Ensayo clínico piloto, aleatorizado, controlado con placebo, paralelo, doble ciego, para evaluar el efecto de salbutamol intravenoso sobre marcadores de inflamación en pacientes con síndrome de distrés respiratorio agudoEUCTR2005-005951-16-ESDr. Joan Ramon Masclans. Servicio de Medicina Intensiva. Hospital Universitario Vall d'Hebron